vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and Research Solutions, Inc. (RSSS). Click either name above to swap in a different company.

Research Solutions, Inc. is the larger business by last-quarter revenue ($11.8M vs $11.0M, roughly 1.1× C4 Therapeutics, Inc.). Research Solutions, Inc. runs the higher net margin — 4.6% vs -186.0%, a 190.6% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs -1.0%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs -1.3%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

Jacobs Solutions Inc. is an American international technical professional services firm based in Dallas. The company provides engineering, technical, professional, and construction services as well as scientific and specialty consulting for a broad range of clients globally, including companies, organizations, and government agencies. Jacobs has consistently ranked No. 1 on both Engineering News-Record (ENR)'s 2018, 2019, 2020, 2021, 2022, and 2023 Top 500 Design Firms and Trenchless Technolo...

CCCC vs RSSS — Head-to-Head

Bigger by revenue
RSSS
RSSS
1.1× larger
RSSS
$11.8M
$11.0M
CCCC
Growing faster (revenue YoY)
CCCC
CCCC
+113.8% gap
CCCC
112.8%
-1.0%
RSSS
Higher net margin
RSSS
RSSS
190.6% more per $
RSSS
4.6%
-186.0%
CCCC
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
-1.3%
RSSS

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
CCCC
CCCC
RSSS
RSSS
Revenue
$11.0M
$11.8M
Net Profit
$-20.5M
$546.9K
Gross Margin
52.4%
Operating Margin
-210.1%
6.3%
Net Margin
-186.0%
4.6%
Revenue YoY
112.8%
-1.0%
Net Profit YoY
40.7%
127.6%
EPS (diluted)
$-0.09
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
RSSS
RSSS
Q4 25
$11.0M
$11.8M
Q3 25
$11.2M
$12.3M
Q2 25
$6.5M
$12.4M
Q1 25
$7.2M
$12.7M
Q4 24
$5.2M
$11.9M
Q3 24
$15.4M
$12.0M
Q2 24
$12.0M
$12.1M
Q1 24
$3.0M
$12.1M
Net Profit
CCCC
CCCC
RSSS
RSSS
Q4 25
$-20.5M
$546.9K
Q3 25
$-32.2M
$749.4K
Q2 25
$-26.0M
$2.4M
Q1 25
$-26.3M
$216.5K
Q4 24
$-34.6M
$-2.0M
Q3 24
$-24.7M
$669.0K
Q2 24
$-17.7M
$-2.8M
Q1 24
$-28.4M
$76.3K
Gross Margin
CCCC
CCCC
RSSS
RSSS
Q4 25
52.4%
Q3 25
50.6%
Q2 25
51.0%
Q1 25
49.5%
Q4 24
48.9%
Q3 24
47.9%
Q2 24
46.5%
Q1 24
45.2%
Operating Margin
CCCC
CCCC
RSSS
RSSS
Q4 25
-210.1%
6.3%
Q3 25
-306.4%
7.8%
Q2 25
-441.0%
9.7%
Q1 25
-402.9%
4.4%
Q4 24
-728.4%
0.8%
Q3 24
-183.9%
5.4%
Q2 24
-178.6%
5.5%
Q1 24
-1060.2%
0.7%
Net Margin
CCCC
CCCC
RSSS
RSSS
Q4 25
-186.0%
4.6%
Q3 25
-286.4%
6.1%
Q2 25
-402.6%
19.0%
Q1 25
-363.7%
1.7%
Q4 24
-667.8%
-16.6%
Q3 24
-160.6%
5.6%
Q2 24
-147.6%
-23.3%
Q1 24
-933.2%
0.6%
EPS (diluted)
CCCC
CCCC
RSSS
RSSS
Q4 25
$-0.09
$0.02
Q3 25
$-0.44
$0.02
Q2 25
$-0.37
$0.08
Q1 25
$-0.37
$0.01
Q4 24
$-0.50
$-0.07
Q3 24
$-0.35
$0.02
Q2 24
$-0.26
$-0.09
Q1 24
$-0.41
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
RSSS
RSSS
Cash + ST InvestmentsLiquidity on hand
$74.6M
$12.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$256.6M
$17.2M
Total Assets
$359.1M
$44.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
RSSS
RSSS
Q4 25
$74.6M
$12.3M
Q3 25
$58.8M
$12.0M
Q2 25
$78.2M
$12.2M
Q1 25
$51.3M
$9.9M
Q4 24
$55.5M
$7.7M
Q3 24
$59.6M
$6.9M
Q2 24
$73.1M
$6.1M
Q1 24
$89.7M
$4.2M
Stockholders' Equity
CCCC
CCCC
RSSS
RSSS
Q4 25
$256.6M
$17.2M
Q3 25
$154.4M
$15.6M
Q2 25
$174.1M
$13.9M
Q1 25
$195.1M
$11.2M
Q4 24
$216.0M
$11.1M
Q3 24
$242.7M
$12.8M
Q2 24
$247.1M
$11.7M
Q1 24
$258.3M
$14.1M
Total Assets
CCCC
CCCC
RSSS
RSSS
Q4 25
$359.1M
$44.2M
Q3 25
$265.5M
$45.5M
Q2 25
$296.5M
$46.1M
Q1 25
$319.5M
$45.2M
Q4 24
$349.6M
$42.8M
Q3 24
$376.1M
$41.4M
Q2 24
$381.1M
$41.9M
Q1 24
$398.4M
$40.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
RSSS
RSSS
Operating Cash FlowLast quarter
$-22.1M
$1.4M
Free Cash FlowOCF − Capex
$1.4M
FCF MarginFCF / Revenue
11.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
2.53×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
RSSS
RSSS
Q4 25
$-22.1M
$1.4M
Q3 25
$-31.2M
$1.1M
Q2 25
$-12.1M
$2.3M
Q1 25
$-33.3M
$2.9M
Q4 24
$-17.9M
$1.0M
Q3 24
$-24.1M
$843.1K
Q2 24
$-5.0M
$2.0M
Q1 24
$-18.1M
$2.0M
Free Cash Flow
CCCC
CCCC
RSSS
RSSS
Q4 25
$1.4M
Q3 25
$-31.6M
$1.1M
Q2 25
Q1 25
$2.9M
Q4 24
$-17.9M
Q3 24
$-24.1M
Q2 24
$-5.2M
$1.9M
Q1 24
$2.0M
FCF Margin
CCCC
CCCC
RSSS
RSSS
Q4 25
11.7%
Q3 25
-281.5%
8.8%
Q2 25
Q1 25
22.8%
Q4 24
-346.5%
Q3 24
-157.2%
Q2 24
-43.1%
16.0%
Q1 24
16.6%
Capex Intensity
CCCC
CCCC
RSSS
RSSS
Q4 25
0.1%
Q3 25
3.7%
0.1%
Q2 25
Q1 25
0.0%
Q4 24
0.1%
Q3 24
0.1%
Q2 24
1.6%
0.1%
Q1 24
0.0%
0.0%
Cash Conversion
CCCC
CCCC
RSSS
RSSS
Q4 25
2.53×
Q3 25
1.48×
Q2 25
0.96×
Q1 25
13.36×
Q4 24
Q3 24
1.26×
Q2 24
Q1 24
26.43×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CCCC
CCCC

Segment breakdown not available.

RSSS
RSSS

Transactions$6.6M56%
Platforms$5.2M44%

Related Comparisons